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for Patients with High-Risk Myelodysplastic
Syndrome or Secondary Acute Myeloid Leukemia
Using a FLAMSA-Based High-Dose Sequential
Conditioning Regimen
Christian Saure, Thomas Schroeder, Fabian Zohren, Anke Groten, Ingmar Bruns,
Akos Czibere, Lars Galonska, Mustafa Kondakci, Christian Weigelt, Roland Fenk,
Ulrich Germing, Rainer Haas, Guido KobbePatients suffering from high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)
secondary to MDS (sAML) are characterized by poor response to conventional cytotoxic chemotherapy.
The purpose of our prospective single-center study was to examine the safety and efficacy of an allogeneic
hematopoietic stem cell transplantation (HSCT) following a sequential conditioning regimen as first-line
therapy for previously untreated patients with high-risk MDS or sAML. Between November 2003 and
June 2010, 30 patients (20 high-risk MDS, 10 sAML) received fludarabine (4  30 mg/m2), amsacrine
(4  100 mg/m2), and Ara-C (4  2 g/m2, FLAMSA). After 2 to 3 days of rest, patients received high-dose
melphalan alone (200 mg/m2 for patients with an age\50 years, 150 mg/m2 for patients with an age between
50 and 60 years, and 100 mg/m2 for patients with an age .60 years; n 5 24) or melphalan and thiotepa
(10 mg/kg, Mel/Thio, n 5 6). Following these high-dose conditioning regimens, a median number of
7.7  106 CD341 cells/kg body weight (range: 2.9  106-17.2  106) were transplanted from 13 related
or 17 unrelated donors. Antithymocyte globulin (Fresenius 30-60 mg/kg) as well as tacrolimus and mycophe-
nolate mofetil were used for graft-versus-host disease (GVHD) prophylaxis. All patients except 1 with pri-
mary graft failure achieved complete remission after HSCT. After a median follow-up time of 28 months
(range: 7-81), 21 patients (70%) were alive and free of disease. Overall, 4 patients relapsed. At 2 years, overall
survival, event-free survival, and treatment-related mortality were 70%, 63%, and 30%, respectively. Because
of undue toxicity, thiotepa is no longer part of the conditioning regimen. Our results add to the body of
evidence that a FLAMSA-based sequential conditioning therapy is effective for previously untreated patients
with high-risk MDS or sAML.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is a treatment for patients with high-risk
myeloid malignancies, including patients with myelo-
dysplastic syndrome (MDS) and acute myelogenous
leukemia (AML) secondary to MDS (sAML) [1-6].
Cutler et al. [7] showed that patients belonging to
the intermediate 2 risk group or high-risk group
according to the International Prognostic Scoring Sys-
tem have the longest overall life expectancy if trans-
planted at diagnosis, whereas patients with low-risk
disease benefit from a wait-and-see approach with
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allogeneic HSCT, patients with high-risk MDS or
sAML still have a high risk of relapse as well as an
increased rate of treatment-related mortality (TRM),
resulting in inferior long-term survival [8-14].
The role of reducing the tumor burden by a con-
ventional induction regimen is controversial. So far,
most patients in Europe received an induction regimen
and then proceeded to allografting as soon as they had
achieved a partial or full remission. This approach is
associated with an inherent selection bias as patients
with high-risk MDS or sAML usually respond poorly
to conventional induction chemotherapy [15-17] and
a considerable number of them develop infectious
complications precluding them from allografting. In
the United States, a substantial number of patients
received high-dose conditioning therapies followed
by allogeneic HSCT without prior induction chemo-
therapy. Retrospective evaluations of this ‘‘upfront’’
strategy conducted at the Fred Hutchinson Cancer
Research Center and the Kansai Medical University
did not show a benefit of pretransplantation induction
chemotherapy for patients with MDS or sAML with
regard to posttransplantation relapse-free survival
(RFS) and overall survival (OS) [18,19], whereas
randomized studies addressing this question had not
been performed.
The FLAMSA-sequential conditioning regimen
developed by Kolb and coworkers [20-22] has shown
promising results in high-risk patients with relapsed
and refractory myeloid malignancies. Following
administration of fludarabine, amsacrine, and Ara-C
(FLAMSA), patients received a conditioning regimen
consisting of low-dose total body irradiation (TBI)
and cyclophosphamide (CY) or busulfan early during
FLAMSA-induced cytopenia followed by allogeneic
HSCT [20-22].
In light of these encouraging findings, we
conducted a prospective single-center study in previ-
ously untreated patients with high-risk MDS and
sAML using an upfront FLAMSA-based sequential
conditioning regimen and allogeneic HSCT. The
results that we observed in this particular group of
30 patients confirms the efficacy of this ‘‘upfront’’
treatment modality.PATIENTS AND METHODS
Patients
Thirty previously untreated patients (10 female,
20 male) were included in a single-center study at the
Heinrich-Heine-University Hospital (Duesseldorf,
Germany), which scheduled upfront sequential condi-
tioning using FLAMSA-Mel/Thio for patients with
high-risk MDS or sAML. All patients who presented
with high-risk MDS between November 2003 andJune 2010, who were eligible for allogeneic transplan-
tation and for whom a donor could be identified during
a considerable time period were included. Ten of 30
patients transformed to AML during the search for
a HLA-compatible donor.
For inclusion, the patient’s age had to be .18
years. For donor selection, HLA-typing was per-
formed using molecular methods (PCR-SSP, PCR-
SSOP, and DNA sequencing) for all loci (HLA-A,
-B, -C, -DR, and -DQ). For 13 patients, a related do-
nor was available, whereas 17 patients received their al-
lografts from unrelated donors. HLA-identical donors
were available in 26 patients, whereas 3 patients had
unrelated donors with 1 mismatch (1 HLA-B allelic
mismatch and 2 HLA-C antigenic mismatches), and
1 patient had an unrelated donor with 2 mismatches
(HLA-B allelic and HLA-C antigenic mismatch).
The median time from diagnosis to transplantation
was 134 days (range: 39-5403).
Concomitant diseases were scaled using the He-
matopoietic Cell Transplantation Comorbidity Index
(HCT-CI; Table 1) [23-25]. All patients received
peripheral blood stem cells collected following
mobilization with granulocyte colony-stimulating
factor. At the time of analysis in January 2011, the me-
dian follow-up time for surviving patients was 28
months (range: 7-81).
The detailed characteristics of the patients are
given in Table 1.
Preparative Regimen
Patients received fludarabine 30 mg/m2 (total dose
120 mg/m2), amsacrine 100 mg/m2 (total dose
400 mg/m2), and high-dose cytarabine 2 g/m2 (total
dose 8 g/m2) therapy from days –9 to –6. High-dose
conditioning therapy consisted of melphalan (day –2,
n5 24) or melphalan and thiotepa (day –2, –3, n 5 6).
The dose of melphalan was adapted to the patient’s
age as follows: \50 years: 200 mg/m2, 50-60 years:
150 mg/m2, and .60 years: 100 mg/m2). Thiotepa at
a dose of 10 mg/kg body weight (BW) was given to 6
patients with an age of\55 years.
Except for 8 with HLA-identical sibling donors,
the patients received rabbit antithymocyte globulin
(Fresenius, Munich, Germany) at a dose of 3  10
mg/kg BW in 7 patients and 3  20 mg/kg BW in 15
patients on days –5, –4, and –3.
Graft-versus-Host Disease (GVHD) Prophylaxis
and Supportive Care
Immunosuppressive therapy following allografting
consisted of tacrolimus (day –1 aiming at concentra-
tions between 10 and 15 ng/mL) and mycophenolate
mofetil (started 1 hour after HSCT at a dose of
15 mg/kg BW). In the absence of GVHD, mycophe-
nolate mofetil was halved on day 128 and
Table 1. Patients’ Characteristics
Values
Number of patients 30
Sex, no. (%)
Female 10 (33)
Male 20 (67)
Median age at transplantation (range) 49 (36-66)
Diagnosis, no. (%)
Primary MDS 12 (40)
Therapy-related MDS 8 (27)
AML secondary to MDS 10 (33)
WHO classification for MDS at
transplantation, no. (%)
MDS (RCMD) 2 (7)
MDS (RAEB I) 8 (27)
MDS (RAEB II) 7 (23)
CMML 3 (10)
IPPS for primary MDS at
transplantation, no. (%)
INT-2 6 (20)
High 3 (10)
WPSS for primary MDS at
transplantation, no. (%)
High 6 (20)
Very High 3 (10)
Cytogenetic subgroups, no. (%)
Good 12 (40)
Intermediate 7 (23)
Poor 11 (37)
Therapy before transplantation, no. (%)
None 30 (100)
Comorbidity Index (HCT-CI), no (%)
0 12 (40)
1 5 (17)
2 2 (7)
3 5 (17)
>3 6 (20)
Median time from diagnosis to
transplantation
d (range) 134 (39-5403)
Stem cell source, no. (%)
Peripheral blood stem cells 30 (100)
Donor type, no. (%)
Fully matched unrelated donor 13 (43)
Partially matched unrelated donor 4 (13)
Fully matched sibling donor 13 (43)
Median no. CD34+ cells within the
graft,  106/kg BW (range)
7.7 (2.9-17.2)
RCMD indicates refractory cytopeniawith multilineage dysplasia; RAEB,
refractory anemia with excess blasts; CMML, chronic myelomonocytic
leukemia; IPPS, International Prognostic Scoring Sytem; INT, intermedi-
ate; WPSS, WHO classification-based prognostic scoring system.
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mus was started between day 180 and day 1100. The
aim was to be off immunosuppressive therapy between
days 120 and 140.Granulocyte colony-stimulating fac-
tor starting as early as 1 day posttransplantation was
given to hasten neutrophil recovery in 17 patients
(57%). The usual standard supportive care was used
as described before [26].
Monitoring and Definitions
After patients were discharged from the hospital,
they were seen in the outpatient clinic twice a week
up to day 1100. Afterward, the intervals were
increased depending on clinical course. Grading of
acute and chronic GVHD (aGVHD, cGVHD) wasperformed according to the usual criteria [27-29].
Toxicities were graded using the National Cancer
Institute Common Toxicity Criteria (CTC), version
2.0. At days 128, 1100, and 1360 disease response
and chimerism were assessed in bone marrow (BM)
and peripheral blood. Complete remission (CR)
was defined as \5% blasts in the BM, no evidence
of dysplasia, as well as restoration of neutrophils
.1500/mL in the peripheral blood. Leukocyte
engraftment was defined as the first of 3 consecutive
days of white blood cell count .1000/mL, and
the day of platelet engraftment was defined as the
first of 7 consecutive days with platelet counts
of .50,000/mL.
Statistics
Event free survival (EFS), RFS, OS, and TRM,
as well as GVHD-onset were calculated from the day
of transplantation to the respective event. Death—
independent of its cause—ever was rated as an event
for the estimation of OS. Death from any cause and
relapse were counted as an event in case of EFS. All
time-to-event curves were estimated by using the
Kaplan-Meier method [30]. For comparison of group
characteristics, a chi-square test and Student t test
were used for univariate analysis. Univariate analysis
was performed for age, sex, presence of cytogenetic ab-
normalities, donor type, percentage of blasts in the
BM, presence of comorbidities, cytomegalovirus sta-
tus, antithymocyte globulin dosage, number of trans-
planted CD341 cells, and time from diagnosis to
transplantation. The statistical analyses were per-
formed using SPSS statistical software.RESULTS
Hematologic Reconstitution and Chimerism
Although all patients developed an individually
varying degree of neutropenia as a consequence of
the FLAMSA therapy, hematologic reconstitution fol-
lowing allografting was observed in all of them but 1.
For neutrophil recovery, a median time of 13 days
(range: 9-31) was required. Taken together, the
period of FLAMSA-related and of posttransplantation
neutropenia the median duration of CTC grade IV
neutropenia was 18 days (range: 11-39). As far as plate-
let reconstitution is concerned, the median time to
reach a stable platelet count of .50/nL was 17 days
(range: 8-56). Looking for donor chimerism in BM
at days 128 and1100, we found a median proportion
of 100% at both time points (range: 89.6%-100% at
day 130 and 78.9%-100% at day 1100).
GVHD, Toxicity, and Infections
Acute GVHD developed in 22 patients (73%) at
a median time of 34 days (range: 11-153) after
Figure 1. Overall survival (OS) and event-free survival (EFS). *Follow-
ing second-line therapy with 5-azacytidine and DLI, all 4 relapsed
patients are still alive and free of disease.
Biol Blood Marrow Transplant 18:466-472, 2012 469Upfront Allogeneic HSCT following FLAMSA for High-Risk MDS and sAMLtransplantation. According to theNational Institutes of
Health criteria, 11 patients (37%) had classic aGVHD
and 11 (37%) late aGVHD. Of these, 6 patients had
a persistent subtype (20%), 4 patients late onset
(13%), and 1 patient a recurrent subtype (3%). Skin,
liver, and gut were affected in 11, 11, and 11 patients,
respectively. As far as the severity is concerned, there
were 16 patients (53%) with grade I-II aGVHD and 6
(20%) with grade III-IV aGVHD (3 with HLA-
identical donors and 3with unrelated donors, including
1 of them with HLA-C antigenic mismatch). Five of
these 6 patients died of complications related to the
severe aGVHD. Thirteen patients who developed
aGVHD are currently alive and free of disease.
Chronic GVHD not including late aGVHD was
observed in 19 patients of 25 patients who had survived
more than 100 days following allografting. Of these,
14 (56%) had limited cGVHD, whereas 5 of them
(20%) suffered from extensive cGVHD. Two
patients developed extensive GVHD following the ad-
ministration of donor lymphocytes (DLI) for the treat-
ment of relapse or incomplete chimerism on days
1307 and 1498, respectively. According to the
National Institutes of Health, cGVHD was graded as
mild in 10 patients (40%), moderate in 4 patients
(16%), and severe in 5 patients (20%). The median
interval from transplantation to onset of de novo
cGVHD was 133 days (range: 100-307). Seventeen
of 19 patients with cGVHD are currently alive and
free of disease. Two patients suffering from extensive
cGVHD died on days 1368 and 1626. It should be
noted that 4 of the 19 patients (21%) who had devel-
oped cGVHD are currently without immunosuppres-
sive therapy and any signs of cGVHD.
For the treatment of GVHD, systemic corticoste-
roids were administered in 22 patients, whereas 5
patients received monoclonal antibodies (Basiliximab,
n 5 1; Infliximab, n 5 1; Etanercept, n 5 1; Basilixi-
mab 1 Infliximab, n 5 1; Basiliximab 1 Etanercept,
n 5 1) because of steroid-refractory disease. Using
univariate analysis, we could not define any patient
characteristic or parameter before transplantation
indicating a particular risk of developing aGVHD or
cGVHD.
Looking at the treatment-related complications in
general, 17 patients developed grade III-IV toxicities
according to the National Cancer Institute-CTC 2.0.
Infectious complications were most prominent with
16 patients who had fevers of unknown origin and 6
patients with pneumonia (Aspergillus spp, n 5 2;
Candida spp, n5 1; and bacterial pneumonia n5 3) ac-
cording to radiological criteria. Grade III-IVmucositis
was seen in 15 patients. Organ toxicity related to liver
was noted in 9 patients, central nervous system in
2, and 4 patients had cardiac problems such as atrial
fibrillation. Light and moderate renal toxicity limited
to grades I and II was transient, except for 1 patientwho developed acute renal failure and died of
pneumonia 4 weeks later. There was also 1 patient
with a venous-occlusive disease. A total of 7 patients
required treatment on our interdisciplinary intensive
care unit for a median time of 28 days (range: 2-115
days).
Disease Response, Relapse, and Survival
At day 128 after allogeneic HSCT, 29 of 30
patients (97%) achieved CR. At the time of writing
this report, 21 patients (70%) are alive and free of
disease (Figure 1). The group of 21 patients in CR in-
cludes 33% who received melphalan/thiotepa and
79% who received melphalan alone. The median fol-
low-up time for this group is 28 months (range:
7-81). Concentrating on the patients with sAML,
8 of 10 patients (80%) are still alive and free of
disease after a median follow-up of 24 months.
Four patients who had received melphalan alone
relapsed on days190,1377,1764, and1853, reflect-
ing an RFS of 93% at 2 years (Figure 2). Remarkably,
following second-line therapy, all of these patients are
still alive and free of disease, with the longest follow-up
of 50 months. All received azacytidine and DLI after
transplantation. Two patients achieved a CR, 1 patient
converted to 100% donor chimerism but remained
thrombocytopenic, and none of these patients relapsed
so far. The fourth patient—also responding to azaciti-
dine andDLIwith a partial response (PR)—underwent
a second transplantation with FLAMSA-treosulfan
conditioning therapy. There were 9 patients who
died between days 144 and 1626 (median, day 181)
Figure 2. Cumulative incidence of relapse.
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4 patients of 6 (67%) who had received melphalan/
thiotepa and 5 of 24 (21%) who had received melpha-
lan alone (Figure 3). This observation prompted us
early to remove thiotepa from the protocol. Looking
at the patients with a fatal outcome in more detail,
the causes of death were related to infectious complica-
tions in 2 patients, to GVHD in combination with
infectious disease in 5 patients, whereas 2 patients
developed thrombotic microangiopathy. At 2 years,
EFS was 63%.Figure 3. Treatment-related mortality.The risk of treatment-related death was related to
the development of aGVHD grade III-IV (5 of 6
patients died), whereas an age of\50 years was associ-
ated with a better probability for survival (P5 .04). In
univariate analysis, there was no other pretransplanta-
tion variable associated with OS.DISCUSSION
The results of this single-center study show that
a FLAMSA-based high-dose therapy is an efficacious
first-line treatment for patients with high-risk MDS
or sAML. A similar regimen has been shown to be
very successful in patients with relapsed and refractory
myeloid malignancies [21,22]. Different from the
original protocol proposed by Kolb et al. [20-22], we
omitted CY and low-dose TBI and used high-dose
melphalan alone or in combination with thiotepa.
The idea behind this change was to avoid the more
intensive immunosuppression related to CY and
TBI, also assuming that melphalan per se or in combi-
nation with thiotepa could exert a stronger antileuke-
mic efficacy. The latter combination was abandoned
because of undue toxicity, whereas the age-adapted
high-dose therapy with melphalan alone was generally
well tolerated.
Looking at the efficacy of the sequential therapy,
we can note that with a median follow-up time of 28
months, 21 of the 30 patients (70%) are alive and
free of disease. Concentrating on the patients who
received melphalan alone, the proportion of those re-
maining alive is 79%. So far, only 4 patients (13%)
have relapsed in our study. It is worth noting that all
of them responded to treatment with azacitidine and
DLI, 3 with CR and 1 with PR. The latter received
a second transplant with FLAMSA-treosulfan condi-
tioning. All patients have remained in CR since then.
Our observations support the results of Czibere et al.
[31] and L€ubbert et al. [32], showing the efficacy of
azacitidine in combination with DLI for patients
with MDS who relapse after allogeneic HSCT. Nei-
ther karyotype, comorbidity, nor the number of blasts
in BMwere of prognostic relevance with regard to RFS
or OS. Still, patients younger than 50 years had a lon-
ger OS in comparison to the patients with an age .50
years (P 5 .04). The cumulative rate of TRM in our
study was 30% for all patients and 21% for patients
who had received melphalan monotherapy. This is in
line with the results of other clinical trials using stan-
dard myeloablative conditioning [12-14,33,34].
Sequential conditioning using the combination of
FLAMSAwithmelphalan requires 9 days of treatment.
Following the allogeneic peripheral blood stem cell
transplantation, we observed full donor chimerism
on day128 in 29 of 30 patients (97%). With a median
time of 18 days of severe neutropenia, this critical
period was shorter than observed following
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MDS/AML [5,35,36]. Independent of the relatively
rapid hematologic recovery, the most relevant
toxicity was related to aGVHD (73%), which
developed at a median time of 34 days (range:
11-153). Patients with grade III-IV aGVHD required
intensive immunosuppressive therapy, leading to in-
fectious complications associated with a mortality
rate of 83%. In order to decrease the probability of re-
lapse in high-risk MDS patients, GVHD prophylaxis
was tapered between day 80 and 100 and discontinued
around day 140. This is shorter than the usual 6
months of immunosuppressive treatment and may be
1 reason for the low relapse rate, but also for a high
incidence of late aGVHD.
Our ‘‘upfront’’ approach using a FLAMSA-based
high-dose therapy with HSCT is based on data
published by Cutler et al. [7] showing that patients be-
longing to the intermediate 2 or high-risk group ac-
cording to the International Prognostic Scoring
System have the greatest life expectancy if transplanted
at diagnosis without delay. This avoids the increasing
risk for acquiring comorbidities. For instance, there
is the risk of accumulation of iron when the transplan-
tation is postponed in favor of supportive care only or
conventional cytotoxic chemotherapy [1,37].
We have to point out that the patients in this study
had a relative stable disease, allowing us to search for a
donor without the need of early treatment. This is cru-
cial, especially for patients with fast transformation to
AML, where the tempo of disease often makes it nec-
essary to applicate chemotherapy as soon as possible.
Considering an ‘‘upfront’’ approach with allograft-
ing, the role of an anteceding induction chemotherapy
with regard to the probability of RFS and OS is still
not answered. In a French trial including 70 patients
with tMDS or tAML, an improved survival was
observed for those patients who had achieved CR
before they proceeded to high dose and allografting
compared with patients with active disease [36].
Therefore, as it has been shown by several other inves-
tigators, the ‘‘leukemic burden’’ at the time of
high-dose therapy is a major prognostic factor for
patients with MDS who undergo myeloablative or
dose-reduced conditioning regimens before allog-
rafting [38,39]. On the other hand, there are 2
retrospective studies of patients with MDS or sAML
conducted at the Fred Hutchinson Cancer Research
Center and Kansai Medical University that did not
find a beneficial effect of induction therapy before
allogeneic HSCT [18,19].
Pondering the pros and cons with regard to induc-
tion therapy, we believe that ‘‘induction-sensitive’’
patients in CR represent a particularly favorable group
with improved outcome following allografting. In con-
trast, patients who have resistant disease following
conventional chemotherapy may not benefit frominduction attempts, as they are not likely to enter
remission, whereas they are at great risk of additional
toxicity. This view is supported by results of the
recently published CRIANT study. There were 194
of 341 patients (57%) with high-risk MDS who
achieved a (CR or PR) remission as a result of induc-
tion therapy [6]. Still, the proportion of patients
undergoing an allogeneic blood stem cell transplanta-
tion was only 15%, clearly showing that many patients
are ‘‘lost on the way to transplant’’ because of poor re-
sponse to chemotherapy or treatment complications
during induction chemotherapy.
In summary, the results of our study indicate that
an ‘‘upfront’’ sequential conditioning therapy using
FLAMSA followed immediately by high-dose melpha-
lan offers an efficient treatment modality for patients
with high-risk MDS and sAML.ACKNOWLEDGMENT
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